Drug Profile
Gallium-68-HBED PSMA
Alternative Names: (68Ga)PSMA-HBED-CC - Grupo RPH Radiopharmacus; 68Ga-HBED-CC-PSMA - Grupo RPH Radipharmacus; HBED-PSMA-Ga68 - Grupo RPH Radiopharmacus; PSMA-HBED-CC GA-68 - Grupo RPH RadiopharmacusLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Radiopharmacus
- Developer Grupo RPH Radiopharmacus
- Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 27 Sep 2023 Preclinical development in Prostate cancer is ongoing in Brazil (Grupo RPH pipeline, September 2023)
- 01 Dec 2016 Radiopharmacus plans a phase III trial for Prostate cancer (diagnosis) in Brazil (RBR26w4cr)
- 01 Oct 2016 Preclinical trials in Prostate cancer (Diagnosis) in Brazil (IV) before October 2016 (RBR26w4cr)